Vesugen (20mg Vial) Dosage Protocol
Khavinson vascular short-peptide bioregulator (KED) — research-only; not approved, benefits unproven.
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers. Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →Mix & measure Vesugen · 20 mg
Dosing & Reconstitution Guide
A single practical dilution with accurate once-daily dosing, step by step
Standard / Gradual Approach (3 mL = 6.67 mg/mL)
Reconstitute: Add 3.0 mL bacteriostatic water to one 20 mg vial → final concentration 6.67 mg/mL (6,667 mcg/mL).
Typical daily range: 500–2000 mcg once daily, raised gradually over an 8–12 week course (optionally extended to ~16 weeks).
Easy measuring: At 6.67 mg/mL, 1 unit ≈ 66.7 mcg on a U-100 syringe. The small starting dose (500 mcg ≈ 7.5 units) reads best on a 30- or 50-unit syringe.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Why Vesugen draws research interest
These are the directions researchers and the peptide community most often explore Vesugen for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
Vascular & endothelial function
The primary reason people look up Vesugen: explored in Khavinson bioregulator research on blood-vessel wall and endothelial cells.
Cardiovascular aging
Investigated in preclinical work on the aging vascular system; research-only KED peptide, not an approved cardiovascular therapy.
Circulation & blood pressure
Studied in animal and lab models for effects on vascular tone and circulation; benefits remain unproven in humans.
Longevity & peptide bioregulation
Researched as part of the Khavinson short-peptide bioregulator class explored for tissue-specific aging; investigational, not approved.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
Quickstart Highlights
Vesugen is a synthetic tripeptide (Lys-Glu-Asp, “KED”) — a Khavinson “cytogen” derived from the active sequence of Ventfort, a vascular-tissue extract, and proposed to act on the vascular endothelium (the blood-vessel wall)[1][2]. This educational page outlines a once-daily subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks. It is an unapproved research chemical, not a medicine, and its proposed benefits are not validated in controlled human trials — presented for research and educational use only.
Add 3.0 mL bacteriostatic water to one 20 mg vial → 6.67 mg/mL (6,667 mcg/mL).
500–2000 mcg once daily, titrated upward gradually across an 8–12 week course (optionally extended to ~16 weeks).
At 6.67 mg/mL, 1 unit ≈ 66.7 mcg; 500 mcg ≈ 7.5 units and 1500 mcg ≈ 22.5 units on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
Frequency: one subcutaneous injection each day, titrating up as tolerated over the course[3][4]. These figures come from Khavinson-affiliated reference protocols, not from validated human dosing.
Reconstitution Steps
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
At 6.67 mg/mL, the early 500 mcg dose is only ~7.5 units, so a 30- or 50-unit insulin syringe reads it most precisely. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Supplies Needed
Quantities below assume an 8–16 week course of once-daily injections with gradual titration.
One 20 mg vial covers roughly 10–20 days depending on the daily dose, so plan a few vials per 8–16 week course.
- 8 weeks: ~4–5 vials
- 12 weeks: ~6–8 vials
- 16 weeks: ~8–10 vials
- Per injection: 1 syringe
- 8 weeks (once daily): ~56 syringes
- 16 weeks (once daily): ~112 syringes
Use ~3.0 mL per 20 mg vial for reconstitution.
- 8 weeks: ~12–15 mL → 2 bottles
- 16 weeks: ~24–30 mL → 3 bottles
One for the vial stopper + one for the injection site each day.
- Per injection: 2 swabs
- 8 weeks (once daily): ~112 swabs → 1–2 boxes
Protocol Overview
A concise summary of the once-daily regimen, drawn from Khavinson-affiliated reference protocols.
- ▪Goal: Proposed support of vascular-endothelial function through the KED tripeptide — an epigenetic/gene-expression hypothesis from in-vitro work, not an established clinical effect[5][6].
- ▪Schedule: Daily subcutaneous injections for 8–12 weeks, optionally extended to ~16 weeks for longer research goals.
- ▪Dose Range: 500–2000 mcg per day with gradual titration over the cycle.
- ▪Reconstitution: 3.0 mL bacteriostatic water per 20 mg vial gives 6.67 mg/mL (1 unit ≈ 66.7 mcg).
- ▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.
Dosing Protocol
A suggested daily titration approach based on common reference doses.
- ▪Start: Begin at 500 mcg once daily to gauge tolerability.
- ▪Titrate: Step up roughly week by week (e.g. 500 → 1,000 → 1,500 mcg) as tolerated.
- ▪Target: Reach about 1,500–2,000 mcg daily from roughly week 4 onward.
- ▪Cycle Length: Typically 8–12 weeks; some references extend to ~16 weeks.
- ▪Timing: Inject at a consistent time each day and rotate injection sites systematically.
Storage Instructions
Correct storage is what preserves the peptide’s stability and activity.
- ▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
- ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8].
- ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
- ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.
Important Notes
Practical points that keep daily administration safe and consistent.
- ▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
- ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
- ▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow.
- ▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
- ▪Regulatory note: Vesugen is not FDA- or EMA-approved for human use; it is not specifically named by WADA, though the S0 “non-approved substances” catch-all may apply in sport[10].
How This Works
Vesugen is a synthetic tripeptide, Lys-Glu-Asp (KED) — one of the Khavinson “cytogen” short peptides[1][2]. Its sequence corresponds to the active fragment of Ventfort, a vascular-tissue peptide extract, and it is proposed to target the vascular endothelium (the blood-vessel wall).
The proposed mechanism is epigenetic: in cell-culture work, KED is reported to influence the expression of genes in vascular endothelial cells — for example Ki-67, endothelin-1, connexin and SIRT1[5][6]. These are in-vitro observations and a hypothesis, not a demonstrated clinical effect.
Vesugen is among the better-published peptides of this class, but essentially all of the evidence comes from Khavinson-affiliated Russian investigators with little or no independent replication[11]. The human studies that exist are small, non-randomized and not placebo-controlled[12].
Important caveat: vascular-rejuvenation, endothelial-renewal and anti-aging claims are not established. They rest on in-vitro data and small unblinded reports, and should be read as hypotheses — not as proven outcomes.
Vesugen is not an approved medicine. It is an unapproved research chemical presented here for research and educational purposes only.
Lifestyle Factors
General habits that support vascular and metabolic health alongside the protocol.
- ▪Nutrition: Favor a balanced, vascular-friendly diet (vegetables, healthy fats, adequate protein).
- ▪Activity & rest: Pair regular movement with genuine recovery time and avoid overtraining.
- ▪Sleep: Aim for 7–9 hours to support the body’s natural repair processes.
- ▪Stress: Manage stress with evidence-based practices, since it influences overall healing.
Potential Benefits & Side Effects
What the (largely in-vitro and single-group) literature describes; independent human evidence is essentially absent and individual results vary.
Potential Benefits
- ▪Endothelial gene expression (in vitro): Cell-culture studies report changes in markers such as Ki-67, endothelin-1 and connexin in vascular cells — a proposed, not proven, mechanism[5][6].
- ▪Reported by proponents: Khavinson-affiliated work has proposed roles in vascular tone and cellular aging markers — without independent replication[11].
- ▪Tolerability (limited): Reported as generally well tolerated in the small available studies, with occasional mild injection-site reactions.
- ▪Note on humans: These benefits are not established — no adequately powered, randomized, placebo-controlled human trials of Vesugen exist[13].
Common Side Effects
- ▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
- ▪Unknown long-term profile: Human safety data is limited, so caution and monitoring are advised.
- ▪Sport caution: Vesugen is not specifically named by WADA, but as a non-approved substance the S0 catch-all may apply to athletes.
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[14][15].
Pre-Injection Preparation
- ▪Wash your hands well with soap and water.
- ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
- ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15].
- ▪Draw the intended dose, then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch a skinfold at the chosen site between thumb and forefinger.
- ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14].
- ▪Skip aspiration for subcutaneous shots — it isn’t needed[14].
- ▪Press the plunger slowly and steadily until it’s fully down.
- ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
- ▪Return the reconstituted vial to the fridge right away.
- ▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9].
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides.
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
Khavinson short peptides (PubMed)Overview of Khavinson peptide bioregulators, including the KED (Lys-Glu-Asp) tripeptide marketed as Vesugen.
- 2
Vesugen / KED tripeptide (PubMed)KED (Lys-Glu-Asp), the active tripeptide of the vascular extract Ventfort, marketed as Vesugen.
- 3
Khavinson vascular peptide studies (PubMed)Reference protocols and reports on KED/Vesugen in vascular research from Khavinson-affiliated groups.
- 4
St. Petersburg Institute of Bioregulation and GerontologyOriginating institute for the Khavinson cytogen peptides, including KED (Vesugen).
- 5
Epigenetics / gene expression (PubMed)In-vitro reports that KED peptide modulates gene expression (e.g. Ki-67, endothelin-1, connexin, SIRT1) in vascular cells.
- 6
Vascular endothelium peptide regulation (PubMed)Proposed effects of short peptides on vascular endothelial cells — in-vitro and hypothesis-level evidence.
- 7
Peptide Storage GuideBest practices for storing lyophilized peptides (temperature, humidity and light protection).
- 8
Bacteriostatic Water GuidanceBacteriostatic water for injection: multi-dose vial stability and handling.
- 9
NCBI BookshelfBest practices for subcutaneous injection: aseptic technique and site rotation.
- 10
WADA Prohibited ListS0 “non-approved substances” category — Vesugen is not named individually but the catch-all may apply.
- 11
Evidence base — single-group literature (PubMed)Most KED/Vesugen reports originate from Khavinson-affiliated investigators with limited independent replication.
- 12
Human study quality (PubMed)Available human reports on KED-class peptides are small, non-randomized and not placebo-controlled.
- 13
ClinicalTrials.govTrial registry search — no completed, registered efficacy trials of Vesugen/KED are listed.
- 14
Centers for Disease Control and Prevention (CDC)Subcutaneous injection technique: angle, site and no-aspiration guidance.
- 15
Subcutaneous Injection Technique (Patient Education)How to administer a subcutaneous injection: clinical technique guidelines.
- 16
Prime Lab PeptidesResearch-peptide supplier — purity specifications and certificates of analysis.
Vesugen — frequently asked questions
How many mg of Vesugen per day, and how long is a cycle?
The schedule documented on this page is not a single fixed number: it references 500 mcg once daily in week 1, 1,000 mcg once daily in week 2, 1,500 mcg once daily in week 3, then 1,500 to 2,000 mcg once daily from week 4 onward. In milligrams that is a range of roughly 0.5 mg to 2 mg per day, reached by gradual titration rather than started at the top. Cycle length is documented as 8 to 12 weeks, with some references extending to about 16 weeks. These figures describe reported research handling, not clinical dosing guidance - Vesugen is not approved for human use.
How many insulin syringe units is each Vesugen dose?
Reconstituting the 20 mg vial with 3 mL of bacteriostatic water gives about 6,667 mcg per mL, so one U-100 unit (0.01 mL) holds roughly 67 mcg. On that mix 500 mcg is about 7.5 units (0.075 mL), 1,000 mcg is 15 units (0.15 mL), 1,500 mcg is about 22.5 units (0.225 mL) and 2,000 mcg is about 30 units (0.30 mL). One 20 mg vial therefore covers roughly 10 to 20 days depending on where in the titration the dose sits.
How do I reconstitute a 20 mg vial of Vesugen?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to Vesugen?
There is no single correct amount — more water simply spreads the same 20 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store Vesugen after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 20 mg vial of Vesugen provide?
Divide the vial strength of 20 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is Vesugen approved for human use?
No. Vesugen is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.